Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.57 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.56 |
| ▸ | CDK4 | P11802 | 2/20 | 0.56 |
| ▸ | CCND1 | P24385 | 2/20 | 0.56 |
| ▸ | CDK9 | P50750 | 2/20 | 0.56 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.56 |
| ▸ | CDK11A | Q9UQ88 | 2/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.54 |
| ▸ | CDK2 | P24941 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6197557 | 0.84 | CCNA2 (0.57) | MAPTCDK5CDK5R1CCNT1CDK4 | |
| SCHEMBL6681628 | 0.83 | CCNA2 (0.67) | MAPTCDK5CDK5R1CCNT1CDK4 | |
| SCHEMBL6634024 | 0.83 | CHRNA7 (0.51) | MAPTCDK5CDK5R1CCNT1CDK4 | |
| SCHEMBL6361686 | 0.83 | CCNT1 (0.65) | MAPTCDK5CDK5R1CCNT1CDK4 | |
| SCHEMBL6632660 | 0.82 | CDK5 (0.60) | MAPTCDK5CDK5R1CCNT1CDK4 | |
| SCHEMBL1250645 | 0.82 | CDK2 (0.72) | MAPTCDK5CDK5R1CCNT1CDK4 | |
| SCHEMBL5727020 | 0.79 | CCNT1 (0.66) | MAPTCDK5CDK5R1CCNT1CDK4 | |
| SCHEMBL6309875 | 0.79 | CCNT1 (0.58) | MAPTCDK5CDK5R1CCNT1CDK4 | |
| SCHEMBL6632625 | 0.79 | CDK2 (0.52) | MAPTCDK5CDK5R1CCNT1CDK4 | |
| SCHEMBL6191533 | 0.79 | CCNA2 (0.63) | CDK5CDK5R1CCNT1CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1438046-A4 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMA (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1438046-A2 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6720346-B2 | (4-AMINOTHIAZOL-2-YLAMINO)-BENZAMIDE COMPOUNDS; PROTEIN KINASE INHIBITORS; CANCER; AUTOIMMUNE, VIRAL, FUNGAL, NEURODEGENERATIVE, AND CARDIOVASCULAR DISORDERS | AGOURON PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | AGOURON PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003004467-A2 | THIAZOLE BENZAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING CELL PROLIFERATION, AND METHODS FOR THEIR USE | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225147-A1 | Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use | TK1, MKI67, CDKN1A | MAPT 2205/4885CDK5 46/4885CDK5R1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.